Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2009 4
2010 1
2011 4
2012 4
2013 3
2014 2
2015 1
2017 4
2018 3
2019 3
2020 4
2021 6
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites.
Muijlwijk T, Nijenhuis DNLM, Ganzevles SH, Brink A, Ke C, Fass JN, Rajamanickam V, Leemans CR, Koguchi Y, Fox BA, Poell JB, Brakenhoff RH, van de Ven R. Muijlwijk T, et al. Among authors: van de ven r. J Immunother Cancer. 2024 Jan 11;12(1):e007573. doi: 10.1136/jitc-2023-007573. J Immunother Cancer. 2024. PMID: 38212122 Free PMC article.
An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy.
Bakema JE, Stigter-van Walsum M, Harris JR, Ganzevles SH, Muthuswamy A, Houtkamp M, Plantinga TS, Bloemena E, Brakenhoff RH, Breij ECW, van de Ven R. Bakema JE, et al. Among authors: van de ven r. Mol Cancer Ther. 2024 Feb 1;23(2):187-198. doi: 10.1158/1535-7163.MCT-23-0298. Mol Cancer Ther. 2024. PMID: 37828725
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors.
King LA, Toffoli EC, Veth M, Iglesias-Guimarais V, Slot MC, Amsen D, van de Ven R, Derks S, Fransen MF, Tuynman JB, Riedl T, Roovers RC, Adang AEP, Ruben JM, Parren PWHI, de Gruijl TD, van der Vliet HJ. King LA, et al. Among authors: van de ven r. Cancer Immunol Res. 2023 Sep 1;11(9):1237-1252. doi: 10.1158/2326-6066.CIR-23-0189. Cancer Immunol Res. 2023. PMID: 37368791
Tumor-educated Tregs drive organ-specific metastasis in breast cancer by impairing NK cells in the lymph node niche.
Kos K, Aslam MA, van de Ven R, Wellenstein MD, Pieters W, van Weverwijk A, Duits DEM, van Pul K, Hau CS, Vrijland K, Kaldenbach D, Raeven EAM, Quezada SA, Beyaert R, Jacobs H, de Gruijl TD, de Visser KE. Kos K, et al. Among authors: van de ven r. Cell Rep. 2022 Mar 1;38(9):110447. doi: 10.1016/j.celrep.2022.110447. Cell Rep. 2022. PMID: 35235800 Free article.
Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapy.
van Duijvenvoorde M, Derks S, Bahce I, Leemans CR, van de Ven R, Fransen MF. van Duijvenvoorde M, et al. Among authors: van de ven r. Clin Transl Immunology. 2022 Jan 10;11(1):e1363. doi: 10.1002/cti2.1363. eCollection 2022. Clin Transl Immunology. 2022. PMID: 35035956 Free PMC article. Review.
NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models.
Gruijs M, Ganzevles SH, Stigter-van Walsum M, van der Mast R, van Ostaijen-Ten Dam MM, Tuk CW, Schilham MW, Leemans CR, Brakenhoff RH, van Egmond M, van de Ven R, Bakema JE. Gruijs M, et al. Among authors: van de ven r. Int J Mol Sci. 2021 Oct 14;22(20):11057. doi: 10.3390/ijms222011057. Int J Mol Sci. 2021. PMID: 34681717 Free PMC article.
Palmitoylated antigens for the induction of anti-tumor CD8+ T cells and enhanced tumor recognition.
Stolk DA, Horrevorts SK, Schetters STT, Kruijssen LJW, Duinkerken S, Keuning E, Ambrosini M, Kalay H, van de Ven R, Garcia-Vallejo JJ, de Gruijl TD, van Vliet SJ, van Kooyk Y. Stolk DA, et al. Among authors: van de ven r. Mol Ther Oncolytics. 2021 Apr 29;21:315-328. doi: 10.1016/j.omto.2021.04.009. eCollection 2021 Jun 25. Mol Ther Oncolytics. 2021. PMID: 34141869 Free PMC article.
45 results